Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities
Metrics: PDF 1379 views | HTML 2395 views | ?
Junnan Wu1,*, Guangtao Lei2,*, Xiao Wang3, Yuezhong Tang4, Huan Cheng4, Guihua Jian1, Xianfeng Wu1 and Niansong Wang1
1Department of Nephrology, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China
2Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
3Department of Endocrinology, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China
4Kangjian Community Health Center, Xuhui District, Shanghai, China
*These authors contributed equally to this work
Niansong Wang, email: [email protected]
Xianfeng Wu, email: [email protected]
Keywords: comorbidities, coronary artery disease, elderly, hyperuricemia, serum uric acid
Received: July 03, 2017 Accepted: September 03, 2017 Published: September 19, 2017
Because many subjects with hyperuricemia have comorbidities, it can be difficult to differentiate the role of hyperuricemia from that of other comorbidities of coronary artery disease (CAD). Subjects aged ≥ 65 years were enrolled in the study and were available at enrollment and at 5-year follow-up. Subjects were excluded if they were overweight or obese, hypertensive, diabetic, hyperlipidemic, had a pre-existing cardiovascular disease, a history of gout or hyperuricemia on medications, or chronic kidney disease as estimated by a glomerular filtration rate (eGFR) < 60 mL/min per 1.73 m2. We used Poisson regression to estimate the hazard ratio (HR) for incident CAD events between hyperuricemic (> 7 mg/dL in men and ≥ 6 mg/dL in women) and normouricemic subjects. A total of 2,142 subjects without comorbidities (mean age of 70.7 ± 5.9 years, 1,194 men) were followed for 57.4 ± 8.9 months. Hyperuricemia was associated with an increased cumulative incidence of incident CAD events (15.0% versus 8.8%, P < 0.001). After adjusting for confounding factors, hyperuricemia independently predicted the risk of incident CAD events (HR=1.71, 95% CI 1.26–2.34). In conclusion, asymptomatic hyperuricemia is a valuable biomarker for predicting the development of incident CAD events.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.